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Background: Many human diseases are correlated with the dysregulation of signal transduction processes. One of
the most important protein interaction domains in the context of signal transduction is the Src homology 2 (SH2)
domain that binds phosphotyrosine residues. Hence, appropriate methods for the investigation of SH2 proteins are
indispensable in diagnostics and medicinal chemistry. Therefore, an affinity resin for the enrichment of all SH2
proteins in one experiment would be desirable. However, current methods are unable to address all SH2 proteins
simultaneously with a single compound or a small array of compounds.
Results: In order to overcome these limitations for the investigation of this particular protein family in future
experiments, a dipeptide-derived probe has been designed, synthesized and evaluated. This probe successfully
enriched 22 SH2 proteins from mixed cell lysates which contained 50 SH2 proteins. Further characterization of the
SH2 binding properties of the probe using depletion and competition experiments indicated its ability to enrich
complexes consisting of SH2 domain bearing regulatory PI3K subunits and catalytic phosphoinositide 3-kinase
(PI3K) subunits that have no SH2 domain.
Conclusion: The results make this probe a promising starting point for the development of a mixed affinity resin
with complete SH2 protein coverage. Moreover, the additional findings render it a valuable tool for the evaluation
of PI3K complex interrupting inhibitors.
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Many human diseases are caused by imbalanced regu-
lation of crucial cellular processes. Cell metabolism is
regulated via a multitude of complex signal transduction
cascades. Signals derived from extracellular stimuli are
forwarded by phosphorylation events, which need to be
strictly controlled. Dysregulation of these signaling pro-
cesses can cause many human diseases such as cancer
[1]. Different protein kinases are key regulators of the
corresponding regulation cascades and, therefore, one of
the most prominent research targets in drug develop-
ment [2,3]. In the initial activation events many protein
complexes are formed in order to initiate phosphoryl-
ation cascades that further activate transcription factors.
Hence, the investigation of these complexes is of major* Correspondence: norbert.sewald@uni-bielefeld.de
†Equal contributors
1Organic and Bioorganic Chemistry, Department of Chemistry, Bielefeld
University, Universitätsstraße 25, 33615 Bielefeld, Germany
Full list of author information is available at the end of the article
© 2014 Höfener et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.importance and still remains challenging since the par-
ticipating proteins are usually expressed at low levels
[4,5]. There are many examples in the literature of kin-
ase inhibitors that were applied in clinical studies or are
available as approved drugs [6]. These kinase inhibitors
usually address the ATP binding domain in the active
(type 1 inhibitors) or inactive (type 2 inhibitors) conform-
ation of the enzyme. The prohibition of protein interac-
tions required for activation of signal transduction kinases
is an alternative strategy for the direct inhibition. The SH2
(Src homology 2) domain that binds to phosphorylated
tyrosine (pY) residues is one of the most important
domains responsible for protein interaction. 120 SH2
domains are present in 110 distinct human proteins
according to the UniProt database and Liu et al. [7-9].
SH2 domain mediated PI3K heterodimer formation is
a prominent example of such a protein interaction. PI3
kinases participate in signal transduction by generating
second messengers that further activate multiple effector
pathways, including Akt-, NF-κB- and Jnk-signaling. PI3l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[10]. Taking this aspect into account, it is not surprising
that addressing the SH2 binding domain is an important
strategy for therapeutic purposes [11]. A mixed kinase
affinity resin for the evaluation of ATP competitive kin-
ase inhibitors, called Kinobeads [12] is available and a
comparable affinity-based approach for the evaluation
of SH2 addressing inhibitors would be desirable. Kino-
beads consist of different affinity probes immobilized
on a solid phase and have been proven to capture a
major part of the human kinome by addressing the ATP
binding pocket. They are used to investigate the kinase
target spectrum and for the determination of binding
affinities in competition experiments with ATP com-
petitive drugs [12]. A mixed SH2 domain affinity resin
that addresses the majority of SH2 containing proteins
would be desirable to adopt this methodology to SH2
proteins. Methods based on a variety of bait peptides
(e.g. pY-peptide chips) have already been developed for
the investigation of these protein-protein interactions
[13,14]. However, coverage of the full range of SH2-
proteins turned out to be problematic. 70 SH2 proteins
could be addressed by utilizing a mixture of 6200 differ-
ent immobilized 13-membered pY-peptides [14]. One
disadvantage of this chip-based method is the require-
ment of SH2-GST fusion proteins for the analysis of the
profiling experiments via anti-GST fluorescent anti-
bodies. An inhibitor affinity purification (IAP) based
approach was established for the investigation of the
EGFR interactome that used at least 24 different immo-
bilized pY-peptides for probing SH2 proteins [15,16].
The IAP approach with the highest amount of captured
SH2 proteins used 57 13-membered pY-peptides immobi-
lized on magnetic beads that captured 45 SH2 proteins
[14]. However, the number of compounds immobilized in
the IAP experiment inversely correlates with the effective
concentration of each immobilized substance [17]. As a
result low abundant SH2 protein members will not be
enriched sufficiently. Hence, all described efforts toAcHN
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Figure 1 Probe design. Probe 1 is based on the peptide inhibitor 2 [18].
function of its linker moiety.develop an IAP approach that covers all 110 human
SH2 proteins were not successful. In this study a small
pY containing dipeptide that only addresses the con-
served pY-core motif addressing the SH2 domain was
used as a probe for the IAP experiment to potentially
overcome these limitations in the future.
Results/discussion
Design and synthesis
For the IAP approach a linkable probe that carries a SH2
domain affinity group and allows for the immobilization
on a solid support is required (Figure 1) [19]. SH2
domains recognize pY-peptides of at least three to eight
residues and consist of two major binding pockets, the
highly conserved pY pocket and the hydrophobic pY+3
pocket [20]. Both regions were shown to be essential
for SH2 ligand binding and are, therefore, highly con-
served [21]. The two point interaction mode induced
by the conserved pY and pY+3 pocket is also known as
“two-pronged plug two-holded socket” binding model
[11]. In addition to the conserved binding regions
further binding pockets are mainly responsible for the
specificity of the ligand recognition. Hence, for the
development of specific ligands such additional pockets
are often addressed e.g. pY-2 to pY+3 (VIpYFVP) or
pY-1 to pY+5 (GpYLPQTV) [22]. In addition, cyclic
peptidomimetics that are less flexible have been devel-
oped for selective inhibition of distinct SH2 proteins
[23]. In order to create a SH2 protein probe that is
potent towards SH2 proteins but not selective for a
specific protein a small peptide that only addresses pY
to pY+3 seems appropriate for the inhibitor moiety. All
natural SH2 ligands contain a pY residue and it was
shown that the omission of the phosphate group de-
creased the binding affinity towards SH2 domains
significantly. In general, a pY residue is essential for a
potent probe and, therefore, has to be incorporated
into the probe structure. Glutamic acid in pY+1 pos-
ition is known to have a flexible binding pattern [21]AcHN
H
N N
O
O
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P
F
F
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It can be immobilized on a solid support via the primary amine
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SH2-protein affinity resin. N-Acetylated phosphotyro-
sine residues are present in many SH2 inhibitors and,
therefore, may be considered as potential moiety for
the probe structure. The SH2 domain inhibitor 2 that
was previously applied for a thermodynamic and struc-
tural study on SH2 domains [18] was chosen as starting
point for the probe development, since it consists of
several key moieties for a potent SH2 domain probe
with broad SH2 protein affinity. Additionally, X-ray
crystal structures of SH2 proteins co-crystallized with
inhibitor 2 are available to determine potential linker
modification sites. Another key feature of inhibitor 2 is
its non-hydrolysable phosphotyrosine building block
that was incorporated into the molecule without sig-
nificant loss of biological activity. One of the inhibitor’s
pentyl residues was chosen for linker modification,
since it points outside the binding site. Molecular dock-
ing analysis was used to confirm similar target binding
properties of probe 1 compared to inhibitor 2 [18]. The
binding mode of the modified pYE SH2 ligand 1 (probe 1)
is in accordance with the original inhibitor 2 (Figure 2)
[24]. Due to the chosen linker modification the pY+2 is
rationally not addressed by the probe, but the attached
alkyl chain addresses the pY+3 binding pocket. For the
alkyl chain that addresses the pY+3 pocket, the small
flexible n-pentyl chain as it can be found in inhibitor 2,
was kept in the probe molecule in order to cover a
broad spectrum of SH2 proteins [25]. However, the
results of the docking experiments revealed that the pY
+2 pocket may be occupied by the oligoethyleneglycol
linker (Figure 2). These findings indicate that probe 1 is
a promising candidate for the IAP approach. As shown
in Figure 2, the phosphonic acid is mainly stabilized by
electrostatic interactions with the side chains of R158,Figure 2 Target binding properties of probe 1. X-ray crystal structure o
domain (PDB: 1a08). Probe 1 was docked to that protein structure and theR178, S180, T182 and T183 and the amide protons of
R158, E181, T182 and T183 (amino acid positions
adopted from PDB: 1a08). The aryl moiety of the pY
residue is stabilized via cation-π-interactions with R158
and R178. The carbonyl groups of the N-acetyl group,
the pY backbone and the glutamic acid side chain inter-
act with H204. In addition, the carbonyl group of the
glutamic acid side chain is also stabilized by electro-
static interactions with Y205. The pentyl residue binds
to a hydrophobic pocket formed by Y205, I217, T218
and L240.
According to the synthesis described by Vu et al. [5],
probe 1 can easily be obtained using manual solid phase
peptide synthesis on a 2-chlorotrityl resin. The required
F2pmp building block was directly synthesized by cop-
per mediated cross coupling of an organozinc compound
in analogy to published procedures [26-31].
SH2 enrichment
The probe was immobilized on sepharose beads and
pull-down experiments were performed using mixed cell
lysates (Colo205, K562, Ovcar8 and SKNBE2). Since the
utilized cell lines feature different protein profiles, a mix
of these lysates offers a versatile pool of proteins for
pull-down experiments. This cell lysate mix was used for
protein kinase enrichment before and performed well,
which led to the conclusion, that it might also contain a
high variety of other signaling-related proteins such as
SH2 proteins. Therefore, this mixed cell lysate was
chosen for the first pull-down experiments (Additional
file 1). Captured proteins were eluted from the beads,
digested with trypsin and identified using liquid chroma-
tography tandem mass spectrometry (LC-MS/MS). This
analysis gave 1557 proteins in total, including 22 SH2-
proteins. SH2 proteins have been enriched with anf the pYE SH2 ligand 2 [18] (yellow) in complex with the c-Src-SH2
docking pose incorporated into that complex (atom specific coloring).
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proteins compared to the summed intensities for all
other identified proteins from the MS experiment. In
order to minimize unspecific binding the pull-down ex-
periment was optimized (Additional file 2) using 10%
glycerol in the washing step (Figure 3). The correspond-
ing results included 1168 proteins in total, of which 20
were SH2-proteins with an intensity ratio of 7.8%. In the
full proteome data of the single cell lines (without prior
enrichment with probe 1) the intensity ratio of SH2 pro-
teins varies from 0.06% to 0.18%. This shows that the
enrichment with probe 1 under optimized conditions
with the mixed cell lysate increases the SH2 protein
abundance by a factor of 43 to 87 (compare Figure 3).
This clearly shows that SH2-proteins have successfully
been enriched by probe 1. Since the mixed cell lysate
covers only 50 out of the 110 known SH2 domain con-
taining proteins (Additional file 3: Figure S2) [9] and low
abundant proteins get diluted by mixing, it is likely that
the comparably small number of identified and enriched
SH2 proteins is an issue of the chosen cell lines, rather
than an issue of the probe. Taking additionally into ac-
count that SH2 proteins are generally less abundantFigure 3 SH2 protein enrichment. The MS-intensity ratio of SH2 proteins
identified SH2 proteins (left y axis). Displayed is full proteome data from Co
pull-down data applying blocked beads and pull-down data applying prob(Additional file 3: Figure S1) underlines the value of
probe 1 for SH2 protein enrichment. According to the
data received by proteome analysis of the NCI-60 cell
line panel [28] the cell line Colo205 features high SH2
protein content (Additional file 3: Figure S1). Therefore,
it was chosen for further experiments. In order to
confirm specific SH2 domain binding, pull-down ex-
periments were performed with lysates derived from
Colo205 cells treated with the phosphatase inhibitor
pervanadate or water as the control (Additional file 4).
The measured differences were quantified with inten-
sity based label free quantification using the MaxQuant
software. In the presence of pervanadate phosphory-
lated tyrosine residues should not be removed by phos-
phatases. Thus, SH2 domains are likely to be occupied
by the excess of naturally occurring pY peptides and
proteins competing with the immobilized bait. Hence,
the amount of enriched SH2 proteins is decreased com-
pared to the control experiment.
Although the Colo205 cell line seemed promising for
further experiments, only 8 SH2 proteins out of 23
present in the Colo205 proteome [28] were successfully
quantified in three replicates. However, PI3K, SRC andin relation to all identified proteins (right y axis) and the number of
lo205, K562, Ovcar8 and SKNBE2 cells (without probe 1 enrichment),
e 1 to mixed cell lysates of Colo205, K562, Ovcar8 and SKNBE2 cells.
Höfener et al. Proteome Science 2014, 12:41 Page 5 of 9
http://www.proteomesci.com/content/12/1/41ABL1 kinase that contain structurally very similar SH2
domains [29] have been reproducibly enriched in all data
sets. These findings indicate that the probe molecule
could be optimized for SH2 proteins with structurally
similar SH2 domains by varying the alkyl based pY+3
binding moiety [29]. According to the “two-pronged
plug and socket” mechanism these results additionally
imply that the probe structure could be varied for pro-
teins containing other SH2 families by incorporating a
different moiety at this position. The triplicate analysis
of the intensity ratios of the SH2 proteins shows that the
amount of enriched SH2 proteins is significantly lower
(7%) for the pervanadate treated samples compared to
14% in the control experiment without pervanadate
(compare Figure 4B). All identified SH2 proteins show a
distinct difference between the pervanadate treated and
the untreated conditions. This implies that the captured
SH2 proteins bind specifically to the probe as expected.
Additionally, in terms of LFQ intensities SH2 protein
enrichment was slightly increased when using Colo205
cells only (Figure 4B) compared to the IAP experiment
with mixed cell lysate (Figure 3). Although probe 1 was
able to specifically enrich SH2 proteins and furthermore
identified 22 different SH2 proteins, more effective SH2
probes are still needed to obtain complete SH2 protein
coverage.
The PI3 kinases are targets of current research [10].
They generate lipid second messengers, act as membrane
docking sites for various downstream effector proteins
and consist of heterodimeric complexes of regulatory,
SH2 domain containing subunits and catalytic subunitsFigure 4 Pull-down experiments applying probe 1 to cell lysates deri
control (triplicates). A: Volcano plot of the measured differences using in
indicated by the SH2-protein LFQ intensity ratio from the MS experiments,
water treated samples from the triplicate analysis. The error bars display th
standard deviation in the pervanadate treated samples mainly originates fr
supplementary information).lacking SH2 domains. The catalytic domains p110α
(PI3KCA), p110β (PI3KCB) and p110δ dimerize each
with any of the regulatory subunits p85α (PI3KR1),
p85β (PI3KR2), p55γ, p55α or p50α [32]. The regula-
tory subunits stabilize the thermally labile catalytic
subunits and inhibit their catalytic activity. Upon cellu-
lar stimulation, these heterodimers are recruited to
membrane proximal pY proteins and the catalytic sub-
units thereby activated. The catalytic subunits PI3KCA
and PI3KCB as well as the corresponding regulatory
subunits (three SH2 domains: [30] C-terminal, internal
and N-terminal) PI3KR1 and PI3KR2 have been enriched
by probe 1 under pervanadate-free conditions. The PI3K
subunits show significantly high differences between the
controls and the pervanadate depleted samples. These
results imply that the regulatory subunits are captured
specifically by an interaction of one of their three SH2
domains with probe 1. Although the catalytic subunits
do not have any SH2 domains, they bind to the probe
and show the same behavior in the pervanadate experi-
ments. This finding shows that the catalytic subunits
are captured as complexes with the regulatory subunits
also under pervanadate untreated conditions. Interest-
ingly, the involved pY residues of the catalytic PI3K sub-
units seem to be relatively stable towards phosphatases,
since the corresponding PI3KCA/PI3KR1 heterodimer
can be enriched in the IAP experiment without phos-
phatase inhibition (Figure 4A). It is very likely that the
capturing proceeds via the N-terminal SH2 domain, be-
cause this domain is not essential for the heterodimer
formation and is structurally very similar to the SH2ved from Colo205 cells treated with pervanadate or water as the
tensity based label-free quantification and B: SH2 protein enrichment
displayed are medians of the intensity ratios of the pervanadate and
e standard deviation between the replicates. The comparably high
om one protein in one of the replicates (for detailed data refer to
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too. These results of the depletion experiments show,
that probe 1 could be applied to evaluate SH2 domain
addressing inhibitors of the participating regulatory
subunits of PI3 kinase complexes.
Another interesting result was obtained for the kin-
ase ABL1 that contains a SH2 domain and was highly
enriched in the pervanadate experiment (Figure 4A).
One possible explanation for this phenomenon could
be that the SH2 domain is conformationally masked
depending on the phosphorylation state of ABL1 and
therefore not enriched under pervanadate conditions.
A similar correlation was previously shown for Tyr70 and
the SH3 domain of ABL1 [31]. However, further experi-
ments are required to investigate that hypothesis.
A competitive binding experiment was performed to
validate the results obtained under pervanadate-depletion
conditions (Additional file 4). Dose response pull-down
experiments were accomplished in Colo205 lysates with
increasing concentrations of the free compound 1 that
competes with the immobilized probe 1 for SH2 domain
binding (Additional file 5). As depicted in Figure 5
probe 1 shows IC50 values in the low micromolar range
(10-23 μM) for the captured regulatory PI3K subunits.
These values are comparable with the data published for
several SH2 domain addressing inhibitors (3-50 μM)
[4,33,34]. Additionally, these findings underscore the
results of the pervanadate depletion experiments that
indicate that the regulatory PI3 kinase subunits specifically102 104 10 6
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Figure 5 Dose-response curves. Pulldown experiments were
conducted using probe 1 with Colo205 cell lysate and increasing
concentrations of the free compound 1.interact with probe 1 via an SH2 domain. The regulatory
PI3K subunits PI3KR1 and PI3KR2 contain a C-terminal
and an N-terminal SH2 domain. The real IC50 values
are likely smaller than the measured values for PI3KR1
and PI3KR2, since it is impossible to distinguish whether
one of the two domains or both simultaneously interact
with equal affinity with probe 1 [35]. As expected all
identified SH2 proteins show a dose dependent decrease
in the competition experiment, whereas the other pro-
teins such as tubulin beta chain (TBB) that is one of the
most abundant proteins in the cell and in the pull-down
results, do not show dose dependent decrease. These
results render probe 1 a valuable tool for the investigation
of PI3K subunit interactions and additionally underline
the potency of probe 1 to bind SH2 domains.
Conclusions
Probe 1 selectively enriches SH2 proteins and allows for
the identification of 22 of the 50 different SH2 proteins
abundant in the chosen lysate with only one substance.
The previously published IAP approach with the highest
amount of captured SH2 proteins used 57 13-membered
pY-peptides immobilized on magnetic beads and cap-
tured 45 SH2 proteins [14]. Therefore, we strongly be-
lieve that our probe is already an improvement and
should be considered as starting point for a full coverage
SH2 protein resin. Such resin could be used for further
SH2 inhibitor design or for the investigation of SH2 pro-
tein interactions. Additionally it could be applied to de-
tect changes in the SH2 proteome of distinct tissues or
cells. Since probe 1 captures two PI3 kinase complexes
it can be applied for the investigation of the participating
SH2 interactions and the evaluation of PI3K complex
interrupting inhibitors. However, a more sufficient cell
lysate for SH2 protein enrichment would be desirable.
Methods
Statistical analysis
A two-tailed student’s t-test assuming equal variance
was performed with log transformed LFQ intensities to
obtain p-values for each protein (p = 0.01 highly sig-
nificant, p = 0.05 significant).
Docking experiment
The docking calculations were performed using Auto-
Dock Vina and AutoDock Tools [24]. All dockings were
conducted as blinds using a search space that fits the
whole protein structure. The figure was built using
UCSF Chimera 1.7 [36].
Sample preparation
Cells were cultivated in humidified air supplemented with
5% CO2 at 37°C using Roswell Park Memorial Institute
160 medium (RPMI1640) for the K562 (DSMZ, Deutsche
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Braunschweig, Germany) and Colo205 (CLS, Cell Lines
Service, Eppelheim, Germany) cells, Dulbecco’s modi-
fied Eagle’s medium (DMEM) for OVCAR8 (Anderson,
Matthew L, Department of Pathology, Baylor College
of Medicine, Houston, Texas) and SKNBE2 (DSMZ,
Deutsche Sammlung von Mikroorganismen und Zellkul-
turen GmbH, Braunschweig, Germany) cells and Iscove’s
modified Dulbecco’s medium (IMDM) for HeLa013
cells. All media were supplemented with 10% fetal
bovine serum (FBS).
For pervanadate treatment, 100 mM sodium vanadate
and 100 mM hydrogen peroxide solution were mixed in
equal amounts resulting in a 50 mM pervanadate solu-
tion. The pervanadate solution was added to the cell
culture medium to a final concentration of 100 μM and
incubated for 25 min at 37°C.
Cells were washed with cold phosphate buffered saline
(PBS) and harvested by lysis using 50 mM Tris/HCl
pH 7.5, 5% Glycerol, 1.5 mM MgCl2, 150 mM NaCl,
0.8% NP-40, 1 mM dithiothreitol and 25 mM NaF with
freshly added protease inhibitors and phosphatase inhibi-
tors (5× phosphatase inhibitor cocktail 1, Sigma-Aldrich,
Munich, Germany, 5× phosphatase inhibitor cocktail 2,
Sigma-Aldrich, Munich, Germany, 1 mM Na3VO4 and
20 nM calyculin A, LC Laboratories, Woburn, MA, USA).
Protein extracts were clarified by centrifugation for
20 min at 100,000 × g at 4°C and protein concentration
was determined by the Bradford method.
Compound coupling
Probe 1 (Additional file 3) was immobilized on sephar-
ose beads through covalent linkage using its primary
amino group [12]. 1 ml of NHS-activated sepharose (GE
Healthcare, Freiburg, Germany) and the compound
(2 μmol/mL beads) were equilibrated in DMSO. 15 μl of
triethylamine was added to start the coupling reaction
and the mixture was incubated on an end-over-end
shaker for 16-20 h in the dark. Free NHS-groups on the
beads were blocked by adding 50 μl aminoethanol and
incubation on an end-over-end shaker for 16-20 h in
the dark. Coupled beads were washed and stored in
ethanol at 4°C in the dark. The coupling reaction was
monitored by LC-MS.
Affinity purification
SH2 probe pulldowns were performed as described
previously [12]. Briefly, cell lysates were diluted with
equal volumes of 1× compound pulldown (CP) buffer
(50 mM Tris/HCl pH 7.5, 5% glycerol, 1.5 mM MgCl2,
150 mM NaCl, 25 mM NaF, 1 mM dithiothreitol and
freshly added protease inhibitors and phosphatase in-
hibitors (5× phosphatase inhibitor cocktail1, Sigma-
Aldrich, Munich, Germany, 5× phosphatase inhibitorcocktail 2, Sigma-Aldrich, Munich, Germany, 1 mM so-
dium pervanadate and 20 nM calyculin A, LC Laboratories,
Woburn, MA, USA)). For the dose response experiment,
lysates were pre-incubated with the free compound for
30 min at 4°C. Lysates were incubated with beads for
30 min at 4°C. Subsequently, the beads were washed
with 1× CP buffers containing 0.4% and 0.2% NP40 and
10% glycerol. Bound proteins were eluted with 2×
NuPAGE LDS Sample Buffer (Invitrogen, Darmstadt,
Germany) and eluates were reduced and alkylated by
50 mM dithiothreitol and 55 mM chloroacetamide.
Samples were then run into a 4–12% NuPAGE gel (Invi-
trogen, Darmstadt, Germany) for about 0.5 cm to concen-
trate the sample prior to in-gel tryptic digestion. In-gel
trypsin digestion was performed according to standard
procedures.
LC-MS/MS measurements
Nanoflow LC-MS/MS was performed by coupling an
Eksigent nanoLC-Ultra 1D + (Eksigent, Dublin, CA) to a
LTQ-Orbitrap XL ETD (Thermo Scientific, Bremen,
Germany). Peptides were delivered to a trap column
(100 μm× 2 cm, packed in-house with Reprosil-Pur C18-
AQ 5 μm resin, Dr. Maisch, Ammerbuch, Germany) at a
flow rate of 5 μL/min in 100% solvent A (0.1% formic
acid in HPLC grade water). After 10 min of loading
and washing, peptides were transferred to an analytical
column (75 μm× 40 cm, packed in-house with Reprosil-
Pur C18-GOLD, 3 μm resin, Dr. Maisch, Ammerbuch,
Germany) and separated using a 210 min gradient from
4% to 32% of solvent B (0.1% formic acid, 5% DMSO in
acetonitrile; solvent A: 0.1% formic acid, 5% DMSO in
water) at 300 nL/minute flow rate. The LTQ Orbitrap XL
was operated in data dependent mode, automatically
switching between MS and MS [2]. Full scan MS spectra
were acquired in the Orbitrap at 60,000 (m/z 400) reso-
lution after accumulation to a target value of 1,000,000.
Tandem mass spectra were generated for up to eight
peptide precursors in the linear ion trap by using
collision-induced dissociation at a normalized collision
energy of 35% after accumulation to a target value of
5,000 for max 100 ms.
Peptide and protein identification and quantification
Raw MS data were processed by MaxQuant (v1.4.0.5) for
peak detection and quantification [37] MS/MS spectra
were searched against the UniProtKB human database
(22.07.13, 88.354 sequences) using the Andromeda search
engine [38] with the following search parameters: full
tryptic specificity, re-quantification and match-between-
runs option, up to two missed cleavage sites, carba-
midomethylation of cystein residues was set as a fixed
modification and N-terminal protein acetylation, me-
thionine oxidation and phosphorylation as variable
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MaxQuant (first search 20 ppm precursor tolerance)
and subsequently re-searched with a mass tolerance
of 10 ppm. Fragment ion mass tolerance was set to
0.5 Da. Search results were filtered to a maximum false
discovery rate (FDR) of 0.01 for proteins and peptides
and a peptide length of at least 7 amino acids was
required.
LFQ intensities of 0 (in control replicates) were re-
placed with the 1% percentile of the LFQ intensities of
this respective measurement for data visualization.
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experiments.
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